Clinical Trial Detail

NCT ID NCT02117479
Title Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements no
Sponsors Incyte Corporation
Indications

pancreatic adenocarcinoma

Therapies

Ruxolitinib

Capecitabine

Age Groups: adult

No variant requirements are available.